Neuroinflammation Program

About Biorchestra

Biorchestra is a private, preclinical-stage biotech founded in 2013, headquartered in Daejeon, South Korea, with a U.S. presence. The company is pioneering RNA interference (RNAi) and messenger RNA (mRNA) therapeutics for challenging neurological conditions, leveraging its proprietary brain-targeted delivery technology. Its strategy involves advancing internal programs while seeking partnerships to expand its platform's application. As a pre-revenue entity, its success hinges on clinical validation of its delivery system and pipeline candidates.

Therapeutic Areas